Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

• Published in: BJS open Vol. 6; no. 5
• Main Authors: Qu, Wei-Feng, Ding, Zhen-Bin, Qu, Xu-Dong, Tang, Zheng, Zhu, Gui-Qi, Fu, Xiu-Tao, Zhang, Zi-Han, Zhang, Xin, Huang, Ao, Tang, Min, Tian, Meng-Xin, Jiang, Xi-Fei, Huang, Run, Tao, Chen-Yang, Fang, Yuan, Gao, Jun, Wu, Xiao-Ling, Zhou, Jian, Fan, Jia, Liu, Wei-Ren, Shi, Ying-Hong
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 02.09.2022
• Subjects: Original

Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen of lenvatinib combined with transarterial chemoembolization (TACE) p...